Skip to Content

Zensana Approval Status

Zensana (ondansetron hydrochloride) is an oral spray 5-HT3 antagonist formulation intended for the prevention of chemotherapy induced nausea and vomiting.

In March 2007, Hana Biosciences announced its plan to withdraw, without prejudice, its pending NDA for Zensana with the FDA.

Development Status and FDA Approval Process for Zensana

Aug  1, 2007Par Pharmaceutical Licenses North American Rights to Zensana from Hana Biosciences
Aug 30, 2006FDA Accepts for Review NDA Filing for Zensana (Ondansetron HCl) Oral Spray
Jun 30, 2006Hana Biosciences Submits Zensana NDA to the FDA
May  9, 2006Hana Biosciences Reaffirms Expected Timing of First NDA Filing

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.